Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with recent acute coronary syndrome

Circulation: Cardiovascular Imaging

Volumn 3, Issue 3, 2010, Pages 298-307

  Tardif, Jean Claude ^a   L'Allier, Philippe L ^a   Ibrahim, Reda ^a   Grégoire, Jean C ^a   Nozza, Anna ^a   Cossette, Mariève ^a   Kouz, Simon ^b   Lavoie, Marc André ^a   Paquin, Janie ^a   Brotz, Tilmann M ^c   Taub, Rebecca ^c   Pressacco, Josephine ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b Centre Hospitalier Regional de Lanaudiere   (Canada)

^c Centre Hospitalier Régional de Lanaudière ^*  (United States)

Author keywords

Atherosclerosis; Coronary disease; Imaging; Inflammation; Leukotrienes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ATORVASTATIN; ATRELEUTON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEUKOTRIENE B4; LEUKOTRIENE E4; PLACEBO; UNCLASSIFIED DRUG; VIA 2291; ARACHIDONATE 5 LIPOXYGENASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; HYDROXYUREA; IODIXANOL; IODOBENZOIC ACID DERIVATIVE; LIPOXYGENASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DYSPNEA; EPISTAXIS; FEMALE; HEADACHE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONCARDIAC CHEST PAIN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; AGED; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT; IMAGE QUALITY; METABOLISM; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PROSPECTIVE STUDY; RADIOGRAPHY; TREATMENT OUTCOME; URINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ARACHIDONATE 5-LIPOXYGENASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYUREA; LEUKOTRIENE B4; LEUKOTRIENE E4; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; OBSERVER VARIATION; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE ENHANCEMENT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TRIIODOBENZOIC ACIDS;

EID: 77953642757     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.110.937169     Document Type: Article

References (23)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
3. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104: 503-516.
4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
5. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20:1262-1275.
6. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque, I: evolving concepts. J Am Coll Cardiol. 2005;46: 937-954.
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
8. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
9. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29-37.
10. Assimes TL, Knowles JW, Priest JR, Basu A, Volcik KA, Southwick A, Tabor HK, Hartiala J, Allayee H, Grove ML, Tabibiazar R, Sidney S, Fortmann SP, Go A, Hlatky M, Iribarren C, Boerwinkle E, Myers R, Risch N, Quertermous T. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum Genet. 2008;123:399-408.
11. De Caterina R, Zampolli A. From asthma to atherosclerosis: 5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med. 2004;350:4-7.
12. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100:1238-1243.
13. Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, Spigonardo F, Bucci M, Cuccurullo F, Prescott SM, Stafforini DM. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665-1670.
14. Lehnigk B, Rabe KF, Dent G, Herst RS, Carpentier PJ, Magnussen H. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J. 1998;11:617-623.
15. Qiu H, Gabrielsen A, Agardh HE, Wan M, Wetterholm A, Wong CH, Hedin U, Swedenborg J, Hansson GK, Samuelsson B, Paulsson-Berne G, Haeggstrom JZ. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A. 2006;103:8161-8166.
16. Allayee H, Hartiala J, Lee W, Mehrabian M, Irvin CG, Conti DV, Lima JJ. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest. 2007;132:868-874.
17. Rola-Pleszczynski M, Stankova J. Leukotriene B4 enhances interleukin-6 (IL-6) production and IL-6 messenger RNA accumulation in human monocytes in vitro: transcriptional and posttranscriptional mechanisms. Blood. 1992;80:1004-1011.
18. Ugolini P, Pressacco J, Lespérance J, Berry C, L'Allier PL, Ibrahim R, Grégoire J, Ouellet R, Heinonen T, Levesque S, Guertin MC, Tardif JC. Evaluation of coronary atheroma by 64-slice multidetector computed tomography: comparison with intravascular ultrasound and angiography. Can J Cardiol. 2009;25:641-647.
19. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 2008;359:2324-2336.
20. Motoyama S, Kondo T, Sarai M, Sugiura A, Harigaya H, Sato T, Inoue K, Okumura M, Ishii J, Anno H, Virmani R, Ozaki Y, Hishida H, Narula J. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol. 2007;50:319-326.
21. Motoyama S, Sarai M, Harigata H, Anno H, Inoue K, Hara T, Naruse H, Ishi J, Hishida H, Wong ND, Virmani R, Kondo T, Ozaki Y, Narula J. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49-57.
22. Bogaty P, Brophy JM, Boyer L, Simard S, Joseph L, Bertrand F, Dagenais GR. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med. 2005;165:221-226.
23. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.